In addition, heat shock protein (HSP) 90 inhibitors are suggested as therapeutic options to overcome resistance on the basis of anti-tumor activity in preclinical models of ALK-driven lung cancer [11, 12] and small-scale clinical trials on ALK-positive lung cancers [13]. This evidence concerns the gene ALK and neoplasm.